Allopurinol attenuates left ventricular dysfunction in rats with early stages of streptozotocin-induced diabetes

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 5, 2012, Pages 409-417

  Gao, Xia ^a   Xu, Yuan ^a   Xu, Bo ^b   Liu, Yanan ^c   Cai, Jun ^a   Liu, Hui Min ^c   Lei, Shaoqing ^c   Zhong, Yin Qin ^d   Irwin, Michael G ^c   Xia, Zhengyuan ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d Shenzhen Futian District Traditional Chinese Medicine Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; EOSIN; HEMATOXYLIN; ISOPROSTANE; PARAFFIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; HEART EJECTION FRACTION; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STAINING; STREPTOZOCIN DIABETES; TISSUE LEVEL; WESTERN BLOTTING;

ALLOPURINOL; ANIMALS; ANTIMETABOLITES; BLOTTING, WESTERN; COLLAGEN TYPE I; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; IMMUNOENZYME TECHNIQUES; ISOPROSTANES; MALE; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84863773463     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2295     Document Type: Article

References (36)

1. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2011; PMID:21626163.
2. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol 2010; 88(3): 233-240.
3. Liu Y, Lei S, Gao X, et al. PKCbeta inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2012; 122(4): 161-173.
4. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010; 56(25): 2115-2125.
5. Xia Z, Kuo KH, Nagareddy PR, et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 2007; 73(4): 770-782.
6. Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2009; 2(5): 259-269.
7. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160(1): 1-40.
8. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75(14): 894-903.
9. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002; 51(4): 1118-1124.
10. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58(1): 87-114.
11. Rajesh M, Mukhopadhyay P, Batkai S, et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med 2009; 13(8B): 2330-2341.
12. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002; 98(1-2): 33-39.
13. Xu J, Beckman JS, Hogan EL, Hsu CY. Xanthine oxidase in experimental spinal cord injury. J Neurotrauma 1991; 8(1): 11-18.
14. Fam SS, Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr Med Chem 2003; 10(17): 1723-1740.
15. Xia Z, Godin DV, Ansley DM. Propofol enhances ischemic tolerance of middle-aged rat hearts: effects on 15-F(2t)-isoprostane formation and tissue antioxidant capacity. Cardiovasc Res 2003; 59(1): 113-121.
16. Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2006; 98(2): 271-279.
17. Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97(19): 1952-1959.
18. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 1999; 277(5 Pt 2): H1967-H1974.
19. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994; 89(1): 345-354.
20. Liu Q, Anderson C, Broyde A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010; 9: 76.
21. Airaksinen J, Ikaheimo M, Kaila J, Linnaluoto M, Takkunen J. Impaired left ventricular filling in young female diabetics. An echocardiographic study. Acta Med Scand 1984; 216(5): 509-516.
22. Amado LC, Saliaris AP, Raju SV, et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 2005; 39(3): 531-536.
23. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104(20): 2407-2411.
24. Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B. Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res 1981; 49(6): 1268-1277.
25. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006; 71(2): 208-215.
26. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003; 5(6): 731-740.
27. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005; 115(3): 509-517.
28. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14(11): 1493-1498.
29. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87(12): 1123-1132.
30. Schaible TF, Malhotra A, Bauman WA, Scheuer J. Left ventricular function after chronic insulin treatment in diabetic and normal rats. J Mol Cell Cardiol 1983; 15(7): 445-458.
31. Pilacik B, Nofer TW, Wasowicz W. F2-isoprostanes biomarkers of lipid peroxidation: their utility in evaluation of oxidative stress induced by toxic agents. Int J Occup Med Environ Health 2002; 15(1): 19-27.
32. Aragno M, Mastrocola R, Alloatti G, et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008; 149(1): 380-388.
33. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004; 261(1-2): 187-191.
34. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22(7): 1186-1190.
35. Riegersperger M, Covic A, Goldsmith D. Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Int Urol Nephrol 2011; 43(2): 441-449.
36. To H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One 2011; 6(11): e27817.